Jim Simons Puma Biotechnology, Inc. Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 1,772,413 shares of PBYI stock, worth $5.55 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,772,413

Previous 1,753,013 1.11%

Holding current value

$5.55 Million

Previous $5.71 Million 20.91%

% of portfolio

0.01%

Previous 0.01%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$2.25 - $4.03 $43,650 - $78,182	19,400 Added 1.11%	1,772,413 $4.52 Million
Q2 2024 Aug 09, 2024	BUY	$2.92 - $5.83 $68,912 - $137,588	23,600 Added 1.36%	1,753,013 $5.71 Million
Q1 2024 May 13, 2024	BUY	$4.29 - $7.4 $241,098 - $415,880	56,200 Added 3.36%	1,729,413 $9.17 Million
Q4 2023 Feb 13, 2024	SELL	$2.23 - $4.49 $119,057 - $239,716	-53,389 Reduced 3.09%	1,673,213 $7.25 Million
Q3 2023 Nov 14, 2023	SELL	$2.63 - $4.09 $82,610 - $128,470	-31,411 Reduced 1.79%	1,726,602 $4.54 Million
Q2 2023 Aug 11, 2023	SELL	$2.6 - $3.58 $199,940 - $275,302	-76,900 Reduced 4.19%	1,758,013 $6.21 Million
Q1 2023 May 12, 2023	BUY	$2.21 - $4.82 $300,714 - $655,857	136,070 Added 8.01%	1,834,913 $5.67 Million
Q4 2022 Feb 13, 2023	SELL	$2.12 - $5.08 $213,736 - $512,160	-100,819 Reduced 5.6%	1,698,843 $7.19 Million
Q3 2022 Nov 14, 2022	SELL	$2.27 - $3.84 $402,409 - $680,728	-177,273 Reduced 8.97%	1,799,662 $4.27 Million
Q2 2022 Aug 12, 2022	BUY	$1.64 - $3.3 $337,348 - $678,810	205,700 Added 11.61%	1,976,935 $5.63 Million
Q1 2022 May 13, 2022	SELL	$2.13 - $3.24 $105,696 - $160,778	-49,623 Reduced 2.73%	1,771,235 $5.1 Million
Q4 2021 Feb 11, 2022	BUY	$2.85 - $6.58 $538,430 - $1.24 Million	188,923 Added 11.58%	1,820,858 $5.54 Million
Q3 2021 Nov 12, 2021	BUY	$6.63 - $9.39 $222,768 - $315,504	33,600 Added 2.1%	1,631,935 $11.4 Million
Q2 2021 Aug 13, 2021	BUY	$8.98 - $11.6 $54,778 - $70,760	6,100 Added 0.38%	1,598,335 $14.7 Million
Q1 2021 May 13, 2021	SELL	$9.38 - $13.63 $649,096 - $943,196	-69,200 Reduced 4.17%	1,592,235 $15.5 Million
Q4 2020 Feb 10, 2021	BUY	$7.78 - $12.13 $853,761 - $1.33 Million	109,738 Added 7.07%	1,661,435 $17 Million
Q3 2020 Nov 13, 2020	BUY	$9.5 - $11.14 $817,000 - $958,040	86,000 Added 5.87%	1,551,697 $15.7 Million
Q2 2020 Aug 13, 2020	BUY	$7.01 - $13.24 $2.64 Million - $4.99 Million	377,100 Added 34.64%	1,465,697 $15.3 Million
Q1 2020 May 14, 2020	BUY	$6.28 - $14.57 $6.22 Million - $14.4 Million	991,097 Added 1016.51%	1,088,597 $9.19 Million
Q4 2019 Feb 13, 2020	BUY	$6.5 - $10.73 $633,750 - $1.05 Million	97,500 New	97,500 $853,000
Q3 2019 Nov 13, 2019	SELL	$8.75 - $12.85 $2.21 Million - $3.24 Million	-252,200 Closed	0 $0
Q2 2019 Aug 12, 2019	BUY	$12.3 - $35.76 $1.97 Million - $5.73 Million	160,300 Added 174.43%	252,200 $3.21 Million
Q1 2019 May 14, 2019	SELL	$20.77 - $42.37 $3.86 Million - $7.87 Million	-185,700 Reduced 66.89%	91,900 $3.57 Million
Q4 2018 Feb 13, 2019	BUY	$20.07 - $46.7 $5.57 Million - $13 Million	277,600 New	277,600 $5.65 Million

Others Institutions Holding PBYI

# of Institutions

101

Shares Held

29M

Call Options Held

50.6K

Put Options Held

16.3K

View Full List

About PUMA BIOTECHNOLOGY, INC.

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $143M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

More about PBYI

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account